New treatment concepts in diffuse large B-cell lymphomas (DLBL): Chemotherapy and biological therapy

Reviews on Recent Clinical Trials

Volumn 2, Issue 2, 2007, Pages 149-162

  Rodriguez, Jose ^a   Gutierrez, Antonio ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Biological therapy; Chemotherapy; Diffuse large B cell lymphomas; New targets; Treatment

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 23573; BORTEZOMIB; CASPASE INHIBITOR; CURCUMIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EVEROLIMUS; GOSSYPOL DERIVATIVE; GX 15070; HEAT SHOCK PROTEIN 90 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OBLIMERSEN; PHOSPHODIESTERASE IV INHIBITOR; PREDNISONE; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN KINASE C INHIBITOR; PSI 341; RITUXIMAB; SMALL INTERFERING RNA; SYNTHETIC PEPTIDE; TEMSIROLIMUS; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER SIZE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG CLEARANCE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; DRUG TREATMENT FAILURE; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; HUMAN; HYPOTHESIS; IMAGING SYSTEM; LARGE CELL LYMPHOMA; MEDICAL DECISION MAKING; MICROARRAY ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; SCINTISCANNING; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE;

EID: 34249065028     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488707780599348     Document Type: Review

References (136)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89(11): 3909-18.
2. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001;13(5): 325-34.
3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329(14): 987-94.
4. Rodriguez J, Cabanillas F, McLaughlin P, et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol 1992; 3 (9): 711-7.
5. Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005; 87: 163-208.
6. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403(6769): 503-11.
7. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(25): 1937-47.
8. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8(1): 68-74.
9. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105(5): 1851-61.
10. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350(18): 1828-37.
11. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue miccroarray. Blood 2004; 103(1): 275-82.
12. Saez AI, Saez AJ, Artiga MJ, et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol 2004; 164(2):613-22.
13. Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 2005; 23(26): 6351-7.
14. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101 (1): 78-84.
15. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99(4): 1136-43.
16. Jerkeman M, Anderson H, Dictor M, Kvaloy S, Akerman M, Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma - a Nordic Lymphoma Group study. Am Hematol 2004; 83(7): 414-9.
17. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63(11-12): 1727-33.
18. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000; 12(5): 450-8.
19. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000; 247(5): 521-34.
20. Ohsawa M, Ikura Y, Fukushima H, et al. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 2005; 68(4-6): 422-31.
21. Covelli A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol 1999; 10 (Suppl 6): 53-9.
22. Sandor V, Wilson W, Fojo T, Bates SE. The role of MDR-1 in refractory lymphoma. Leuk Lymphoma 1997; 28(1-2): 23-31.
23. Cheng AL, Su IJ, Chen YC, Lee TC, Wang CH. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993; 11(1): 109-15.
24. Niehans GA, Jaszcz W, Brunetto V, et al. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 1992; 52(13): 3768-75.
25. Beck WT. Multidrug resistance and its circumvention. Eur J Cancer 1990; 26(4): 513-5.
26. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995; 9(2): 363-82.
27. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 1991; 77(2): 348-54.
28. Trump DL, Smith DC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992; 84(23): 1811-6.
29. Sonneveld P, Wiemer E. Inhibitors of multidrug resistance. Curr Opin Oncol 1997; 9(6): 543-8.
30. Dalton WS. Cellular determinant of drug response provide new targets for cancer therapy. Curr Opin Oncol 2000; 12: 541-542.
31. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5(11): 876-85.
32. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000; 102(1): 1-4.
33. Ravi R, Bedi GC, Engstrom LW, et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 2001; 3(4):409-16.
34. Lossos IS, Natkunam Y, Levy R, Lopez CD. Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. Leuk Lymphoma 2002; 43(12): 2309-17.
35. Muris JJ, Cillessen SA, Vos W, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005; 105(7): 2916-23.
36. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90(1): 244-51.
37. Hachem A, Gartenhaus RB. Oncogenes as molecular targets in lymphoma. Blood 2005; 106(6): 1911-23.
38. Ravi R, Bedi A. Potential methods to circumvent blocks in apoptosis in lymphomas. Curr Opin Oncol 2002; 14(5): 490-503.
39. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396(6711): 580-4.
40. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3(8): 917-21.
41. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96(5): 1921-5.
42. Huang RC, Chang CC, Mold D. Survivin-dependent and - independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acid. Semin Oncol 2006; 33(4): 479-85.
43. Hong SY, Yoon WH, Park JH, Kang SG, Ahn JH, Lee TH. Involvement of two NF-kappa B binding elements in tumor necrosis factor alpha -, CD40-, and epstein-barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J Biol Chem 2000; 275(24): 18022-8.
44. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-kappaB inducers upregulatr cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001; 21(12): 3964-73.
45. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281(5383): 1680-3.
46. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194(12):1861-74.
47. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997; 34(4 Suppl 5): 9-19.
48. Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99(7): 2285-90.
49. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996; 88(3): 1046-51.
50. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes, de l'Adulte (GELA). Blood 1996; 87(1):265-72.
51. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003; 30(5 Suppl 16): 133-42.
52. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18(9): 1812-23.
53. Cotter FE. Antisense therapy for lymphomas. Hematol Oncol 1997; 15(1):3-11.
54. Papadopoulos K. Targeting the Bcl-2 family in cancer therapy. Semin Oncol 2006; 33(4): 449-56.
55. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002; 12(3): 193-213.
56. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005; 5(6): 468-79.
57. Zangemeister-Wittke U, Leech SH, Olie RA, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000; 6(6): 2547-55.
58. Bentires-Alj M, Barbu V, Fillet M, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003; 22(1): 90-7.
59. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5(4): 297-309.
60. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23(4): 667-75.
61. O'Connor OA. The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas. Curr Treat Options Oncol 2004; 5(4): 269-81.
62. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621-63.
63. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5(5): 417-21.
64. Skommer J, Wlodkowic D, Pelkonen J. Cellular foundation of curcumin-induced apoptosis in follicular lymphoma cell lines. Exp Hematol 2006; 34(4): 463-74.
65. Georgakis GV, Li Y, Humphreys R, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005;130(4): 501-10.
66. Ravi R, Bedi A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated. inhibition of Bcl-x(L). Cancer Res 2002; 62(6):1583-7.
67. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104(2):155-62.
68. Hu Y, Cherton-Horvat G, Dragowska V, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003; 9(7): 2826-36.
69. Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60(11); 2805-9.
70. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004; 23(37): 6261-71.
71. Su TT, Guo B, Kawakami Y, et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002; 3(8): 780-6.
72. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106(4): 1164-74.
73. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 2004; 16(6): 564-75.
74. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(4): 235-42.
75. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-celt lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7(5): 379-91.
76. Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol 2003; 30(4):424-33.
77. Emmanouilides C, Jazirehi AR, Bonavida B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002; 17(6): 621-30.
78. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEX1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res 2004; 64(19): 7117-26.
79. Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 2004; 23(20): 3530-40.
80. Jazirehi AR, Gan XH, De Vos S, Emmanouilides C, Bonavida B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-I (Apaf-I) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003; 2(11): 1181-93.
81. Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 2005; 24(55): 8114-27.
82. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001; 61(13): 5137-44.
83. Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol 2005; 175(4): 2174-83.
84. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24(13): 2121-43.
85. Lo Coco F, Ye BH, Lista F, et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 1994; 83(7): 1757-9.
86. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 1997; 276(5312): 589-92.
87. Cattoretti G, Pasqualucci L, Ballon G, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005; 7(5):445-55.
88. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004; 432(7017): 635-9.
89. Jardin F, Sahota SS. Targeted somatic mutation of the BCL6 proto-oncogene and its impact on lymphomagenesis. Hematology 2005; 10(2): 115-29.
90. Artiga MJ, Saez AI, Romero C, et al. A short mutational hot spot in the first intron of BCL-6 is associated with increased BCL-6 expression and with longer overall survival in large B-cell lymphomas. Am J Pathol 2002; 160(4): 1371-80.
91. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000; 13(2): 199-212.
92. Baron BW, Anastasi J, Thirman MJ, et al. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis. Proc Natl Acad Sci USA 2002; 99(5): 2860-5.
93. Kurosu T, Fukuda T, Miki T, Miura O. BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells. Oncogene 2003; 22(29): 4459-68.
94. O'Connor OA. Targeting histones and proteasomes: new strategies for the treatment of lymphoma. J Clin Oncol 2005; 23(26): 6429-36.
95. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005; 23(17): 3971-93.
96. Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002; 32(4): 606-13.
97. Li Z, Wang X, Yu RY, et al. BCL-6 negatively regulates expression of the NF-kappaB1 p105/p50 subunit. J Immunol 2005; 174(1): 205-14.
98. Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res 2006; 12(5): 1547-55.
99. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003; 4(1): 13-8.
100. Sasakawa Y, Naoe Y, Inoue T. et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 2002; 64(7): 1079-90.
101. Takayama S, Reed JC, Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 2003; 22(56): 9041-7.
102. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004; 3(8): 1021-30.
103. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5(10): 761-72.
104. Itoh H, Ogura M, Komatsuda A, Wakui H, Miura AB, Tashima Y. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochem J 1999; 343 (Pt 3): 697-703.
105. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 micel. Cancer Chemother Pharmacol 2001; 47(4): 291-302.
106. Georgakis GV, Li Y, Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 2006; 135(1): 68-71.
107. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis m an RB- and schedule-dependent manner.
108. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001; 7: 2155-2158;
109. Clin Cancer Res 2001; 7(8): 2228-36.
110. Mimnaugh EG, Xu W, Vos M, et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004; 3(5): 551-66.
111. Rahmani M, Yu C, Dai Y, et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 2003; 63(23): 8420-7.
112. Norton L, Simon R, Brereton HD, Bogden AE. Predicting the course of Gompertzian growth. Nature 1976; 264(5586): 542-5.
113. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8(6): 963-77.
114. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004; 22(21): 4302-11.
115. Zelenetz AD. Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma. Oncology (Williston Park) 2003; 17(11 Suppl 11): 21-6.
116. Schmits R, Schmitz N, Pfreundschuh M. The best treatment for diffuse large B-cell lymphoma: a German perspective. Oncology (Williston Park) 2005; 19(4 Suppl 1): 16-25.
117. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99(8): 2685-93.
118. Gregory SA, Trumper L. Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? Ann Oncol 2005; 16(9): 1413-24.
119. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101(11): 4279-84.
120. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107(11): 4207-13.
121. Strehl J, Mey U, Glasmacher A, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 2003; 88(11):1304-15.
122. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350(13):1287-95.
123. Milpied N-J, Deconinck E, Lamy T, Colombat P. Frontline High-Dose Therapy (HDT) for Adults with Disseminated Aggressive Lymphoma (NHL): Analysis of 327 Patients Included in 3 Prospective Trials (GOELAMS 071, 072, 074) over 12 Years. Blood 2005; 106:2076.
124. Betticher D, Martinelli G, Radford J, et al. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol 2006; 17(10): 1546-52.
125. Stewart DA, Bahlis N, Valentine K, et al. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2006; 107(12): 4623-7.
126. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43(8): 1018-27.
127. Cheson BD, Pfistner B, Juweid ME, et al. Revised Response Criteria for Malignant Lymphomas From the Members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma, Represented by: Blood 2005; 106: 18.
128. Verdonck LF, van Putten WL, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332(16):1045-51.
129. Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003; 21(7):1255-62.
130. Ng AP, Lee M, Hogg A, et al. A Mid-Treatment FDG-Positron Emission Tomography (PET) Scan is Highly Predictive of Subsequent Treatment Failure in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood 2005; 106: 1931.
131. Dupuis J, Gaulard P, Itti E, et al. Early Response Evaluation with 18FDG-PET Scanning, but Not Phenotypic Profile, Are Predictive of Outcome in Diffuse Large B-Cell Lymphoma. Blood 2005; 106: 1914.
132. Conde E, Arranz R, Rodriguez J, et al. Treatment Stratification According to Early Response to Mega-CHOP, Based on CT and Gallium 67 Scan (G67S) with or without IFE Salvage Therapy Followed by Peripheral Autologous Stem Cell Transplant (PBSCT) in Patient with Poor Prognosis Aggressive Lymphoma. A Preliminary Report from a Prospective GEL/TAMO Trial. Blood 2005; 106: 3335.
133. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5(4): 275-84.
134. Borzillo GV, Lippa B. The Hedgehog signaling pathway as a target for anticancer drug discovery. Curr Top Med Chem 2005; 5(2):147-57.
135. Cheson BD. Radioimmunotherapy of non-Hodgkin's lymphomas. Curr Drug Targets 2006; 7(10): 1293-300.
136. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24(19): 3121-7.